Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rien Van

Showing results (111-120 of 118) with videos related to

Pageof 12
Sort By:
You have reached the last page of results.This site can display upto 118 results.
Annals of Hematology|April 11, 2013
High-dose imatinib versus high-dose imatinib in combination with intermediate-dose cytarabine in patients with first chronic phase myeloid leukemia: a randomized phase III trial of the Dutch-Belgian HOVON study groupNoortje Thielen, Bronno van der Holt, Gregor E G Verhoef, et al.
British Journal of Haematology|March 10, 2020
Bortezomib maintenance after R-CHOP, cytarabine and autologous stem cell transplantation in newly diagnosed patients with mantle cell lymphoma, results of a randomised phase II HOVON trialJeanette K Doorduijn, Josee M Zijlstra, Pieternella J Lugtenburg, et al.
Nature|June 28, 2023
Galaxies in voids assemble their stars slowlyJesús Domínguez-Gómez, Isabel Pérez, Tomás Ruiz-Lara, et al.
The Journal of Infectious Diseases|November 4, 2017
The Role of B Cells in Carriage and Clearance of Mycoplasma pneumoniae From the Respiratory Tract of MicePatrick M Meyer Sauteur, Ruben C A de Groot, Silvia C Estevão, et al.
Haematologica|August 8, 2024
Hematopoietic cell transplantation for older acute myeloid leukemia patients in first complete remission: results of a randomized phase III studyDietger Niederwieser, Dirk Hasenclever, Wolfgang E Berdel, et al.
Science Immunology|April 26, 2022
An ACE2-blocking antibody confers broad neutralization and protection against Omicron and other SARS-CoV-2 variants of concernWenjuan Du, Daniel L Hurdiss, Dubravka Drabek, et al.
Blood Advances|September 11, 2020
Ibrutinib added to 10-day decitabine for older patients with AML and higher risk MDSGerwin Huls, Dana A Chitu, Thomas Pabst, et al.
Blood Cancer Journal|June 19, 2023
Age and sex associate with outcome in older AML and high risk MDS patients treated with 10-day decitabineJacobien R Hilberink, Isabelle A van Zeventer, Dana A Chitu, et al.
Pageof 12

Showing results (111-120 of 118) with videos related to

Sort By:
Pageof 12
You have reached the last page of results.This site can display upto 118 results.
Annals of Hematology|April 11, 2013
High-dose imatinib versus high-dose imatinib in combination with intermediate-dose cytarabine in patients with first chronic phase myeloid leukemia: a randomized phase III trial of the Dutch-Belgian HOVON study groupNoortje Thielen, Bronno van der Holt, Gregor E G Verhoef, et al.
British Journal of Haematology|March 10, 2020
Bortezomib maintenance after R-CHOP, cytarabine and autologous stem cell transplantation in newly diagnosed patients with mantle cell lymphoma, results of a randomised phase II HOVON trialJeanette K Doorduijn, Josee M Zijlstra, Pieternella J Lugtenburg, et al.
Nature|June 28, 2023
Galaxies in voids assemble their stars slowlyJesús Domínguez-Gómez, Isabel Pérez, Tomás Ruiz-Lara, et al.
The Journal of Infectious Diseases|November 4, 2017
The Role of B Cells in Carriage and Clearance of Mycoplasma pneumoniae From the Respiratory Tract of MicePatrick M Meyer Sauteur, Ruben C A de Groot, Silvia C Estevão, et al.
Haematologica|August 8, 2024
Hematopoietic cell transplantation for older acute myeloid leukemia patients in first complete remission: results of a randomized phase III studyDietger Niederwieser, Dirk Hasenclever, Wolfgang E Berdel, et al.
Science Immunology|April 26, 2022
An ACE2-blocking antibody confers broad neutralization and protection against Omicron and other SARS-CoV-2 variants of concernWenjuan Du, Daniel L Hurdiss, Dubravka Drabek, et al.
Blood Advances|September 11, 2020
Ibrutinib added to 10-day decitabine for older patients with AML and higher risk MDSGerwin Huls, Dana A Chitu, Thomas Pabst, et al.
Blood Cancer Journal|June 19, 2023
Age and sex associate with outcome in older AML and high risk MDS patients treated with 10-day decitabineJacobien R Hilberink, Isabelle A van Zeventer, Dana A Chitu, et al.
Pageof 12